| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Duke University Medical Center, Durham, North Carolina, USA
Correspondence: John A. Bartlett, M.D., Duke University Medical Center, Box 3238, Durham, North Carolina 27710, USA; Telephone: 919-681-6060; Fax: 919-681-8474; e-mail: jab5{at}acpub.duke.edu
Recent progress in antiretroviral treatment has led to dramatic improvements in HIV-related morbidity and mortality. These improvements have been fostered by advances in our understanding of HIV-related pathogenesis, the use of plasma HIV RNA levels to monitor patients, and the availability of 11 licensed antiretroviral drugs, including the potent protease inhibitors. Numerous drug combinations, especially those containing three agents, can suppress plasma HIV RNA levels below the lower limit of detection in the majority of treated patients. However, the limitations of this therapeutic responsepatient compliance, drug resistance, and a residual burden of chronically infected cells which are refractory to treatmentshould be familiar to the oncologist.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |